The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology

the Alzheimer's Biomarker Consortium – Down Syndrome (ABC-DS)

doi:10.1002/dad2.12065

The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology

the Alzheimer's Biomarker Consortium – Down Syndrome (ABC-DS)

Research output: Contribution to journal › Review article › peer-review

Abstract

Introduction: Adults with Down syndrome (DS) are at exceptionally high risk for Alzheimer's disease (AD), with virtually all individuals developing key neuropathological features by age 40. Identifying biomarkers of AD progression in DS can provide valuable insights into pathogenesis and suggest targets for disease modifying treatments. Methods: We describe the development of a multi-center, longitudinal study of biomarkers of AD in DS. The protocol includes longitudinal examination of clinical, cognitive, blood and cerebrospinal fluid-based biomarkers, magnetic resonance imaging and positron emission tomography measures (at 16-month intervals), as well as genetic modifiers of AD risk and progression. Results: Approximately 400 individuals will be enrolled in the study (more than 370 to date). The methodological approach from the administrative, clinical, neuroimaging, omics, neuropathology, and statistical cores is provided. Discussion: This represents the largest U.S.-based, multi-site, biomarker initiative of AD in DS. Findings can inform other multidisciplinary networks studying AD in the general population.

Original language	English (US)
Article number	e12065
Journal	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume	12
Issue number	1
DOIs	https://doi.org/10.1002/dad2.12065
State	Published - 2020

Keywords

ABC-DS
Alzheimer's disease
Down syndrome
dementia

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health

Access to Document

10.1002/dad2.12065

Cite this

@article{925d777f67904d4a931da1593e81388e,

title = "The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology",

abstract = "Introduction: Adults with Down syndrome (DS) are at exceptionally high risk for Alzheimer's disease (AD), with virtually all individuals developing key neuropathological features by age 40. Identifying biomarkers of AD progression in DS can provide valuable insights into pathogenesis and suggest targets for disease modifying treatments. Methods: We describe the development of a multi-center, longitudinal study of biomarkers of AD in DS. The protocol includes longitudinal examination of clinical, cognitive, blood and cerebrospinal fluid-based biomarkers, magnetic resonance imaging and positron emission tomography measures (at 16-month intervals), as well as genetic modifiers of AD risk and progression. Results: Approximately 400 individuals will be enrolled in the study (more than 370 to date). The methodological approach from the administrative, clinical, neuroimaging, omics, neuropathology, and statistical cores is provided. Discussion: This represents the largest U.S.-based, multi-site, biomarker initiative of AD in DS. Findings can inform other multidisciplinary networks studying AD in the general population.",

keywords = "ABC-DS, Alzheimer's disease, Down syndrome, dementia",

author = "{the Alzheimer's Biomarker Consortium – Down Syndrome (ABC-DS)} and Handen, {Benjamin L.} and Lott, {Ira T.} and Christian, {Bradley T.} and Nicole Schupf and Sid OBryant and Mark Mapstone and Fagan, {Anne M.} and Lee, {Joseph H.} and Dana Tudorascu and Wang, {Mei Cheng} and Elizabeth Head and William Klunk and Ances, {Beau M.} and Florence Lai and Shahid Zaman and Sharon Krinsky-McHale and Brickman, {Adam M.} and Rosas, {H. Diana} and Annie Cohen and Howard Andrews and Sigan Hartley and Wayne Silverman and Aizenstein, {Howard J.} and Andrews, {Howard F.} and Karen Bell and Birn, {Rasmus M.} and Peter Bulova and Amrita Cheema and Kewei Chen and Isabel Clare and Lorraine Clark and Cohen, {Ann D.} and Constantino, {John N.} and Doran, {Eric W.} and Eleanor Feingold and Foroud, {Tatiana M.} and Hartley, {Sigan L.} and Rachel Henson and Christy Hom and Lawrence Honig and Ikonomovic, {Milos D.} and Johnson, {Sterling C.} and Courtney Jordan and Kamboh, {M. Ilyas} and David Keator and Kofler, {Julia K.} and Kreisl, {William Charles} and Krinsky-McHale, {Sharon J.} and Patrick Lao and Silverman, {Wayne P}",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association",

year = "2020",

doi = "10.1002/dad2.12065",

language = "English (US)",

volume = "12",

journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",

issn = "2352-8729",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - The Alzheimer's Biomarker Consortium-Down Syndrome

T2 - Rationale and methodology

AU - the Alzheimer's Biomarker Consortium – Down Syndrome (ABC-DS)

AU - Handen, Benjamin L.

AU - Lott, Ira T.

AU - Christian, Bradley T.

AU - Schupf, Nicole

AU - OBryant, Sid

AU - Mapstone, Mark

AU - Fagan, Anne M.

AU - Lee, Joseph H.

AU - Tudorascu, Dana

AU - Wang, Mei Cheng

AU - Head, Elizabeth

AU - Klunk, William

AU - Ances, Beau M.

AU - Lai, Florence

AU - Zaman, Shahid

AU - Krinsky-McHale, Sharon

AU - Brickman, Adam M.

AU - Rosas, H. Diana

AU - Cohen, Annie

AU - Andrews, Howard

AU - Hartley, Sigan

AU - Silverman, Wayne

AU - Aizenstein, Howard J.

AU - Andrews, Howard F.

AU - Bell, Karen

AU - Birn, Rasmus M.

AU - Bulova, Peter

AU - Cheema, Amrita

AU - Chen, Kewei

AU - Clare, Isabel

AU - Clark, Lorraine

AU - Cohen, Ann D.

AU - Constantino, John N.

AU - Doran, Eric W.

AU - Feingold, Eleanor

AU - Foroud, Tatiana M.

AU - Hartley, Sigan L.

AU - Henson, Rachel

AU - Hom, Christy

AU - Honig, Lawrence

AU - Ikonomovic, Milos D.

AU - Johnson, Sterling C.

AU - Jordan, Courtney

AU - Kamboh, M. Ilyas

AU - Keator, David

AU - Kofler, Julia K.

AU - Kreisl, William Charles

AU - Krinsky-McHale, Sharon J.

AU - Lao, Patrick

AU - Silverman, Wayne P

PY - 2020

Y1 - 2020

N2 - Introduction: Adults with Down syndrome (DS) are at exceptionally high risk for Alzheimer's disease (AD), with virtually all individuals developing key neuropathological features by age 40. Identifying biomarkers of AD progression in DS can provide valuable insights into pathogenesis and suggest targets for disease modifying treatments. Methods: We describe the development of a multi-center, longitudinal study of biomarkers of AD in DS. The protocol includes longitudinal examination of clinical, cognitive, blood and cerebrospinal fluid-based biomarkers, magnetic resonance imaging and positron emission tomography measures (at 16-month intervals), as well as genetic modifiers of AD risk and progression. Results: Approximately 400 individuals will be enrolled in the study (more than 370 to date). The methodological approach from the administrative, clinical, neuroimaging, omics, neuropathology, and statistical cores is provided. Discussion: This represents the largest U.S.-based, multi-site, biomarker initiative of AD in DS. Findings can inform other multidisciplinary networks studying AD in the general population.

AB - Introduction: Adults with Down syndrome (DS) are at exceptionally high risk for Alzheimer's disease (AD), with virtually all individuals developing key neuropathological features by age 40. Identifying biomarkers of AD progression in DS can provide valuable insights into pathogenesis and suggest targets for disease modifying treatments. Methods: We describe the development of a multi-center, longitudinal study of biomarkers of AD in DS. The protocol includes longitudinal examination of clinical, cognitive, blood and cerebrospinal fluid-based biomarkers, magnetic resonance imaging and positron emission tomography measures (at 16-month intervals), as well as genetic modifiers of AD risk and progression. Results: Approximately 400 individuals will be enrolled in the study (more than 370 to date). The methodological approach from the administrative, clinical, neuroimaging, omics, neuropathology, and statistical cores is provided. Discussion: This represents the largest U.S.-based, multi-site, biomarker initiative of AD in DS. Findings can inform other multidisciplinary networks studying AD in the general population.

KW - ABC-DS

KW - Alzheimer's disease

KW - Down syndrome

KW - dementia

UR - http://www.scopus.com/inward/record.url?scp=85108596995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85108596995&partnerID=8YFLogxK

U2 - 10.1002/dad2.12065

DO - 10.1002/dad2.12065

M3 - Review article

C2 - 32775597

AN - SCOPUS:85108596995

SN - 2352-8729

VL - 12

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

IS - 1

M1 - e12065

ER -

The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this